No Data
No Data
Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023
Immunotech Biopharm (HKG:6978) reported a loss and total comprehensive expense attributable to owners of approximately 334.8 million yuan for the year ended Dec. 31, 2023, compared with a loss of 318.
Yongtai Bio-B (06978.HK)'s annual loss increased to 335 million yuan
Gelonghui, March 28, 丨 Yongtai Bio-B (06978.HK) announced that for the year ended December 31, 2023, the company's other revenue increased by about RMB 1.4 million or about 15.4% from about RMB 9.1 million in the previous year to about RMB 10.5 million. R&D expenditure increased by approximately RMB 1.1 million, or approximately 0.6%, from approximately RMB 176.2 million in the previous year to approximately RMB 177.3 million in the same year. Total loss and overall expenses during the year increased by approximately RMB321.1 million for the year ended 31 December 2022 by approximately RMB14
Yongtai Bio-B (06978) Announces 2023 Annual Results with R&D Expenses of 177 Million Yuan to Accelerate Research on Expanded Indications for EAL
Yongtai Bio-B (06978) disclosed the 2023 annual results announcement. The company achieved about 1 other revenue during the reporting period...
IMMUNOTECH-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Yongtai Bio-B (06978.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui March 18 | Yongtai Bio-B (06978.HK) announced that the company plans to hold a board meeting on March 28, 2024 (Thursday) to consider and approve (including) the annual results of the company and its subsidiaries for the year ended 31 December 2023 and their announcements.
IMMUNOTECH-B: DATE OF BOARD MEETING
No Data